submit news    HOME | FEEDBACK  


- Bio/Medicine

- Chemicals

- Defense

- Drug Delivery

- Education

- Electronics

- Energy

- Events

- Grants

- Industry

- Investment

- Litigation

- Materials


- Nanofabrication

- Nanoparticles

- Nanotubes

- Optics

- Partnership

- Patent

- Products

- Quantum dots

- Research

- Smart Dust

- Software

- Browse by Month

- Current Shows

- Previous Shows

- Submit Events

Become A Nanotechwire Partner

FEI Company

Veeco Instruments

Nano Science and Technology Institute

National Nanotechnology Initiative

Nanotechnology at Zyvex

Want to see your Company or Organization listed above? Become A Nanotechwire Partner Today - click here


11/4/2003 4:26:59 PM
Caliper Technologies Settles Patent Infringement Suit Against Molecular Devices

Caliper Technologies Corp. today announced that it has settled its patent infringement lawsuit against Molecular Devices Corp. The lawsuit alleged that Molecular Devices' "IMAP" assay products infringe Caliper's U.S. Patent Nos. 6,287,774 (the '774 patent) and 6,472,141 (the '141 patent). In connection with the settlement, Caliper and Molecular Devices have entered into a nonexclusive license agreement pursuant to which Molecular Devices has agreed to pay to Caliper a one-time licensing fee as well as royalties based on future sales of IMAP products. Financial details of the settlement were not disclosed.

The '774 and '141 patents cover methods and systems for performing a wide variety of assays in which the reaction product has a different charge than the substrate. The product (or substrate) is bound to a polyionic component, and the binding is detected by any of a variety of conventional methods, including fluorescence polarization. This method complements other microfluidic approaches, also developed by Caliper, to address important unmet needs in high-throughput pharmaceutical screening.

"We are pleased to have achieved this settlement. Now we can fully dedicate our efforts towards advancing our product pipeline and establishing greater market penetration in the life sciences and automation industries," says Kevin Hrusovsky, President and CEO of Caliper. "Additionally this settlement attests to the strength and value of our intellectual property estate and helps solidify our technology leadership in the area of high throughput screening, including the increasingly important area of kinase screening."

Today, Caliper has over 200 issued U.S. patents and a total portfolio of more than 600 pending and issued patents worldwide, covering microfluidic technology, instrumentation, applications, manufacturing technology, and related software.

Other Headlines from Caliper Technologies ...
 - Caliper Life Sciences Receives $1.1 Million Task Order from the EPA's ToxCast Screening Program
 - Biotech and Pharma Executives Discuss Value of Microfluidic Technologies In Drug Discovery at The International Symposium on Laboratory Automation And Robotics
 - Caliper Technologies Settles Patent Infringement Suit Against Molecular Devices

More Litigation Headlines ...
 - Integran Files Patent Infringement Claims Against Modumetal, Inc.
 - Nanosys Reaches Settlement of Patent Infringement Lawsuit Against Nanoco Technologies for Quantum Dot Technology
 - 3M and EV Group Settle Patent Infringement Suit
 - High Court Rules Oxford University Spin-Out Oxonica Breached Patent License
 - Asylum Research Settles Patent Dispute with Veeco

« Back To List »

- submit company
- submit news
- submit events
- advertise here

- More Events

Copyright 2017 | Privacy Policy |